announces License and Technology Transfer Agreement with TERUMO
Expres: Automated Peritoneal Dialysis System
(October 31, 2001)
Lausanne, Switzerland, October 31, 2001 -
Debiotech, S.A., a privately held Swiss Medical Device company,
announced today that it has entered into a long term development,
license and technology transfer Agreement with Terumo Corporation
Under this Agreement, Terumo acquired exclusive
rights to manufacture and market the new Automated Peritoneal Dialysis
System and related disposable cassette from Debiotech for the Japanese
market. The agreement is based on upfront payments plus royalties
The Renal ExpresTM Automated Peritoneal Dialysis
System is presently under development by Debiotech, together with
its unique patented disposable cassette, and shall provide safe
and cost-effective Peritoneal Dialysis therapy in both hospital
and home care settings. Its small size and lightweight, as well
as Telemedicine remote survey and programming capability with voice-over-data
telephone transmission, represents a significant improvement in
Automated Peritoneal Dialysis offering.
The Renal ExpresTM Pump system is part of
Debiotech's advanced therapeutic and drug delivery systems designed
to meet the growing market need for improved therapeutic systems,
particularly in areas such as the home care environment and chronic
Terumo plans to manufacture and sell the
Renal ExpresTM system and its disposable cassette in Japan under
its brand name, using the already available manufacturing partners
selected by Debiotech.
Dr. Frédéric Neftel, CEO, Debiotech
SA, stated, "We are delighted to enter into a long-term relationship
on Renal ExpresTM with Terumo, which has today the strongest market
presence in Japan in the Medical Devices and Dialysis field. Terumo's
marketing and manufacturing expertise, as well as strong knowledge
in dialysis, will effectively contribute reaching our common objective
towards improving Quality of Life of peritoneal dialysis patients
at home and should ultimately participate to the success of one
of our leading product in Asia."
Dr. Akira Takahashi, Executive Vice President,
Terumo Corp., stated, "The Renal Expres System has big potential
to revolutionize the Peritoneal Dialysis therapy in future. We expect
this new system will contribute to the Q.O.L of dialysis patients
and shift more patients from the Hemo Dialysis therapy to the Peritoneal
Dialysis therapy in Japan, which is helpful for common life in society."
ABOUT DEBIOTECH SA
Debiotech S.A. specializes in the research
and development of innovative medical devices in the field of Dialysis,
IV and nutrition therapy, electronic infusion systems, drug reconstitution
and syringes, flow control, diagnostics, implantable drug delivery
systems and micro-systems for insulin and peptide drug delivery.
ABOUT TERUMO Corporation
Terumo was established in 1921 and has a high market
share of broad range of medical products in Japan and overseas.
Terumo products are reputed for their leading-edge technology in
markets worldwide and are contributing to the healthcare of people
in more than 150 countries.
Head Office: 44-1, Hatagaya 2-chome, Shibuya-ku,
President: Takashi Wachi
Web site: http://www.terumo.com
Paid-in Capital: 38,716 millions of yen (End of March, 2001)
Consolidated Net Sales: 176,049 millions of yen (End of March, 2001)
Number of Employees: 7,438 (End of March, 2001)
Main Business: Manufacture and Sales of medical products, ex. I.V.
solution, blood bags, disposable medical devices, catheters for
angiography and treatment, cardiovascular systems, dialysis systems,
medical electronic products and home medical instruments, etc.